

# Linde M Morsink

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/195212/publications.pdf>

Version: 2024-02-01

11  
papers

152  
citations

1477746

6  
h-index

1372195

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

185  
citing authors

#	ARTICLE	IF	CITATIONS
1	Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning. <i>Blood Cancer Journal</i> , 2022, 12, 6.	2.8	7
2	Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. <i>Blood</i> , 2022, 139, 1694-1706.	0.6	36
3	Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement. <i>Clinical Oral Investigations</i> , 2022, , 1.	1.4	2
4	Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 246-252.	0.6	9
5	CombiFlow: Combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones. <i>Blood Advances</i> , 2021, , .	2.5	4
6	Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 669-672.	1.3	13
7	Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. <i>Leukemia</i> , 2020, 34, 1701-1705.	3.3	15
8	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. <i>Cancers</i> , 2020, 12, 2339.	1.7	28
9	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. <i>Leukemia</i> , 2020, 34, 1577-1587.	3.3	22
10	Diffuse plane normolipaemic xanthomatosis as a manifestation of monoclonal gammopathy. <i>British Journal of Haematology</i> , 2019, 187, 411-411.	1.2	2
11	Novel monoclonal antibody-based therapies for acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 116-126.	0.7	14